Church & Dwight Stock News

Church & Dwight Co., Inc. (NYSE:CHD ) Q3 2024 Earnings Conference Call November 1, 2024 10:00 AM ET Company Participants Matt Farrell - Chairman, President and Chief Executive Officer Rick Dierker - Chief Financial Officer and Head of Business Operations Conference Call Participants Chris Carey - Wells Fargo Securities Rupesh Parikh - Oppenheimer Bonnie Herzog - Goldman Sachs Steve Powers - Deu...

EWING, N.J.--(BUSINESS WIRE)--Church & Dwight Co., Inc. (NYSE: CHD) today announced the Company exceeded its outlook with stronger than expected sales growth and gross margin expansion. In the third quarter, net sales grew 3.8% to $1,510.6 million. The Company drove strong consumer demand across its portfolio in Q3. Organic sales grew 4.3% driven by volume of 3.1% and positive product mix and p...

EWING, N.J.--(BUSINESS WIRE)--Church & Dwight Co., Inc. (NYSE:CHD) today reported that its Board of Directors declared a regular quarterly dividend of $0.28375 cents per share. This quarterly dividend will be payable December 2, 2024 to stockholders of record at the close of business on November 15, 2024. It is the Company's 495th regular consecutive quarterly dividend. Church & Dwight Co., Inc...

EWING, N.J.--(BUSINESS WIRE)--Church & Dwight Co., Inc. (NYSE: CHD) will webcast a discussion of its third quarter earnings results on Friday, November 1, 2024, beginning at 10:00 a.m. ET. Media and investors may access the live audio webcast at https://investor.churchdwight.com/ beginning at 10:00 a.m. ET. The webcast will also be available for replay. Church & Dwight Co., Inc., founded in 184...

The complaint seeks at least $5 million in damages from Ewing, NJ-based Church & Dwight for purchasers of Trojan condoms nationwide.

A new lawsuit on Monday claims that Trojan condoms are not safe because they contain toxic "forever chemicals," which have been linked to cancer.

Morgan Stanley recently downgraded Church & Dwight (NYSE: CHD) from “Overweight” to “Equal-weight” while maintaining a price target of $110. This downgrade signals growing concerns about the stock's limited potential for future gains, as it currently trades near $105, leaving only about a 5% upside.

CHD's share price expected to remain rangebound until positive data supports meeting FY24 organic sales guidance. Recent earnings show mixed performance, with uncertainty surrounding the ability to meet FY24 guidance. Uncertain macroeconomic environment, decelerating volume growth, and expensive valuation relative to peers contribute to a neutral stance on CHD.